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Abstract
Objectives To assess the incidence of acute adverse events (AAEs) in gadolinium-enhanced cardiac magnetic resonance (CMR)
imaging.
Methods Gadolinium-based contrast agent (GBCA)–enhanced CMR data from the multinational, multicenter European Society
of Cardiovascular Radiology MRCT Registry was included. AAE severity was classified according to the American College of
Radiology Manual on Contrast Media (mild, moderate, severe). Multivariable generalized linear mixed effect models were used
to assess the likelihood of AAEs in various GBCA, adjusting for pharmacological stressor, main indications (i.e., suspected or
known coronary artery disease or myocarditis), age, sex, and submitting center as a random effect.
Results In the study population of 72,839 GBCA-enhanced CMRs, a total of 260 AAEs were reported (0.36%), with a minority
of severe AAEs (n = 24, 0.033%). Allergic-like AAEs were less likely than physiologic AAEs (29% versus 71%). Patients
without pharmacological stress imaging had a lower AAE rate (0.22%) compared to stress imaging (0.75%), with the highest
AAE rates for regadenoson (2.95%). AAE rates also varied by GBCA subtype (overall p < 0.001). There was significant
interaction between GBCA and pharmacological stressor (interaction p = 0.025), with AAE rates ranging between 0 and 10%
for certain GBCA/stressor combinations. There was further marginal evidence that higher GBCA volume was associated with
higher AAE incidence (OR = 1.02, p = 0.05).
Conclusion GBCA-enhanced CMR imaging demonstrates low AAE rates comparable to those of other body regions. AAE
likelihood correlates with GBCA subtype, pharmacological stressor, and imaging indication. Intravenous fluid administration in
patients with cardiac impairment might contribute to these findings.
Key Points
• Acute adverse event rates in cardiac magnetic resonance (CMR) imaging with gadolinium-based contrast agents (GBCAs) are
low (0.36%), especially for severe adverse events (0.033%).
• Mild and moderate adverse events are more frequent during stress CMR imaging.
• Physiologic AAEs are more common than allergic AAEs in CMR imaging.
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Gadolinium-based contrast agents (GBCAs) are consid-
ered safe in magnetic resonance (MR) imaging with acute
adverse event rates reported to be ranging from 0.04 to
2.2% [1–7].
Differences in adverse event rates by anatomical region
might originate not only from distinct imaging algorithms
but also from different propensities depending on the patient’s
underlying pathology. In this context, cardiac imaging is of
special interest, with a variety of indications ranging from
cardiac viability assessment in older multimorbid patients to
myocarditis imaging in primarily younger and healthier pa-
tients [8–10].
Moreover, cardiac MR (CMR) imaging for ischemic heart
disease is routinely performed with pharmacological stressors,
which might increase the incidence of acute adverse events in
general, and GBCA-related acute adverse events in specific
[11].
So far, acute adverse events in CMR imaging have
been systematical ly evaluated in the European
Cardiovascular Magnetic Resonance (EuroCMR) Registry
[12]. Adverse event rates ranged from 0.17% in a sample
of 17,767 patients to 0.12% in a sample of 37,788 pa-
tients [5, 13]. However, there is no comprehensive litera-
ture evaluating acute adverse events in GBCA-enhanced
cardiac MR imaging with statistical adjustment for poten-
tial confounders, such as stress test imaging, main indica-
tions, age, and sex.
Therefore, the aim of the current study was to evaluate
data originating from the multicenter, multinational cardi-
ac MRCT Regist ry of the European Society of
Cardiovascular Radiology (ESCR) to assess the likelihood
of gadolinium-associated acute adverse events in cardiac
MR imaging.
Methods
This retrospective study was performed in accordancewith the
Declaration of Helsinki and received institutional review
board approval (Leipzig University, No. 131/17-ek).
The data source of this study is the multinational, mul-
ticenter ESCR MRCT Registry, which includes imaging
studies submitted between 2013 and 2016. Using a stan-
dardized online questionnaire, the physicians responsible
for CMR imaging prospectively provided mandatory infor-
mation on patient characteristics, indications, diagnoses,
imaging techniques, contrast media application, and occur-
rence of acute adverse events (reported as the most severe
event for each patient). Information on GBCA concentra-
tion and volume was non-mandatory. MRCT Registry
users were unaware that data was utilized to assess acute
adverse event incidences, thereby minimizing potential
reporting biases.
Only CMR scans with intravenous administration of
GBCAwere included. GBCA molecular structure was classi-
fied as cyclic or linear, its ionic properties as ionic or non-
ionic, and its thermodynamic chelate stability by log Ktherm
[14]. Covariates included pharmacological stressors, main in-
dication, GBCA volume and concentration, gender, and age.
Imaging indications rather than diagnoses were evaluated to
avoid reverse causation, since acute adverse events might
have influenced diagnoses (i.e., aborted examination or arti-
facts as a consequence of acute adverse events). Five admin-
istrations of gadoversetamide (Optimark®, Medtronic-
Covidien) were excluded from analyses to avoid non-
convergence of the statistical models due to a too small sub-
group size.
Outcomes
Acute adverse events (AAEs) were categorized as allergic-
like or physiologic and classified as mild, moderate, or
severe according to the American College of Radiology
(ACR) Manual on Contrast Media [15]. As the AAE
dyspnea is not specified according to the ACR, it was con-
sidered as physiologic given our study cohort with poten-
tial cardiac impairment. Hypersensitive AAE included ur-
ticaria and hives, as well as those categorized as
hypersensitive without further detail by the treating physi-
cian. AAE category and severity are summarized in
Table 2. Primary study outcome was any acute adverse
event.
Statistics
Descriptive statistics provided are absolute numbers and
percent for categorical variables, and mean and standard
deviation (SD) for continuous variables. For evaluation
of the outcome acute adverse event, multivariable logis-
tic regression models were fit with variable selection
based on univariate significance and clinical knowledge.
A generalized linear mixed effects model (GLMM) with
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submitting institution as a random effect was chosen to
account for institutional differences in patient popula-
tions. A priori, a test for multiplicative interaction be-
tween pharmacological stressor and GBCA was planned.
For sensitivity analyses, the outcomes allergic-like AAE
and physiologic AAE were evaluated. For statistical
modeling, the largest GBCA subgroup of patients re-
ceiving gadobutrol was chosen as reference. All statis-
tics were performed using R (version 3.3.2) and R
Studio (version 1.0.44) [16, 17].
All p values provided are two-sided. An alpha level of 0.05
was chosen for statistical significance.
Results
Baseline characteristics
A total of 72,839 CMR studies submitted to the ESCRMRCT
Registry between 2013 and 2016 fulfilled the inclusion
criteria. CMR studies were performed in 152 distinct partici-
pating centers, the majority of which used either one or two
different GBCA subtypes (n = 53 [34.9%] and n = 38 [25%],
respectively). Figure 1 plots the number of different GBCA
subtypes used by each institution.
Most imaging studies were performed without phar-
macological stressor (74.5%). Older patients and those
with known or suspected coronary artery disease (CAD)
as the main imaging indication were more likely to re-
ceive pharmacological stressors, as shown in Table 1.
The most frequently used GBCA was gadobutrol
(Gadovist®, Bayer Healthcare; n = 40,620, 56%), follow-
ed by gadoteric acid (Dotarem®, Guerbet; n = 14,257,
20%). Baseline parameters stratified by GBCA subtype
are provided in the supplemental material.
Final diagnoses based on CMR imaging were cardio-
myopathy in 10,938 patients (15%), CAD in 9939 pa-
tients (13.6%) and exclusion of CAD in 9409 patients
(12.9%), myocardial infarction in 8228 patients (11.3%),
valve disease in 8174 patients (11.2%), myocarditis in
6302 patients (8.7%), and miscellaneous diagnoses in
23,455 patients. In another 1591 patients (2.2%), CMR
imaging revealed no pathological findings. CMR exam-
inations were aborted in 30 patients due to AAEs yield-
ing no final imaging diagnosis.
Full data on GBCA volume (ml) and molal concentra-
tion (mmol/kg) was available for 18,849 imaging studies
(25.8%). The mean GBCA volume was 18.9 ml (± 10.2),
with higher volumes reported in the regadenoson sub-
group (30.2 ml). Thirty-seven percent of these patients
received gadoteric acid. The mean volume administered
showed a variation depending on the contrast agent used:
the highest volumes for gadoteridol (33.8 ± 7.9 ml),
gadopentetate (27.8 ± 12.9 ml), and gadoteric acid (27.5
± 9.9 ml) compared to gadobutrol (13.4 ± 5 ml),
gadobenate (17.3 ± 5.3 ml), or gadodiamide (18.6 ±
9 ml). The mean gadolinium concentration was 0.17 ±
0.06 mmol/kg bodyweight, with lower concentration for
gadodiamide (0.15 ± 0.05 mmol/kg) and higher concentra-
tions for gadoteridol (0.19 ± 0.04 mmol/kg). This suggests
that the majority of CMR examinations were performed
using a 1.5 or double dose of intravenous Gd-DTPA.
Fig. 1 Frequency of different GBCAs used by each participating institution
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Adverse events
In total, 260 acute adverse events (0.36%) were reported.
According to the ACR criteria [15], the majority of AAEs
were classified as mild (n = 104 [absolute, 0.143%; relative,
40%]) or moderate (n = 132 [absolute, 0.181%; relative,
50.8%]), and only few as severe (n = 24 [absolute, 0.033%;
relative, 9.2%]). Allergic-like AAEs were less likely than
physiologic AAEs (n = 76 [absolute, 0.104%; relative, 29%]
versus n = 184 [absolute, 0.253%; relative, 71%]). The most
frequent acute adverse event was dyspnea (n = 88, 33.8%),
followed by hypersensitive reactions (n = 61, 23.5%) and
emesis (n = 17, 6.5%).
The AAE rate was higher among patients receiving
pharmacological stressors (n = 140/18,554, 0.75%) com-
pared to non-stress imaging (n = 120/54,285, 0.22%,
p < 0.001). Across different pharmacological stressor
subgroups, patients receiving regadenoson had higher
AAE rates (n = 34/1151, 2.95%), when compared to aden-
osine (n = 99/16,921, 0.59%) or dobutamine (n = 7/482,
1.45%), but the only seven severe AAEs (0.041%) asso-
ciated with pharmacological stressors occurred in the
adenosine group.
In addition to acute adverse events, ten extravasations
of GBCA were reported: five in the non-stress group
(0.009%), four in the adenosine group (0.024%), and
one in the regadenoson group (0.087%). Table 2 shows
frequencies of specific acute adverse events in the dataset.
Statistical models for acute adverse events
in GBCA-enhanced cardiac MR imaging
The final multivariable GLMM for AAEs of any sever-
ity included the following covariates: age, gender,


















Age (years) 52 (± 19) 49 (± 20) 62 (± 14) 61 (± 14) 63 (± 12) 64 (± 13)
Gender, n (%)
Male 47,040 (65) 34,506 (64) 12,534 (68) 11,397 (67) 812 (71) 325 (67)
Female 25,799 (35) 19,779 (36) 6020 (32) 5524 (33) 339 (29) 157 (33)
GBCA, n (%)
Gadobutrol (i.e., Gadovist®) 40,620 (56) 30,366 (56) 10,254 (55) 9383 (55) 680 (59) 191 (40)
Gadoteric acid
(i.e., Dotarem®)
14,257 (20) 10,780 (20) 3477 (19) 3014 (18) 430 (37) 33 (7)
Gadobenate
(i.e., MultiHance®)
7092 (10) 4768 (9) 2324 (13) 2182 (13) 16 (1) 126 (26)
Gadopentetate
(i.e., Magnevist®)
5624 (8) 4120 (8) 1504 (8) 1391 (8) 16 (1) 97 (20)
Gadoteridol
(i.e., ProHance®)
2994 (4) 2290 (4) 704 (4) 669 (4) 6 (1) 29 (6)
Gadodiamide
(i.e., Omniscan®)
2252 (3) 1961 (4) 291 (2) 282 (2) 3 (0) 6 (1)
GBCAvolume (ml)
Mean (SD) 18.90 (± 10.23) 18.36 (± 9.97) 20.08 (± 10.7) 19.34 (± 10.1) 30.2 (± 14.1) 21.06 (± 8.8)
Missing, n (%) 44,394 (61) 34,774 (64.1) 9620 (51.9) 8772 (51.8) 578 (50.2) 270 (56.0)
GBCA concentration
(mmol/kg)
Mean (SD) 0.17 (± 0.06) 0.17 (± 0.05) 0.16 (± 0.07) 0.16 (± 0.07) 0.13 (± 0.1) 0.18 (± 0.1)
Missing, n (%) 43,630 (60) 34,283 (63.2) 9347 (50.4) 8515 (50.3) 578 (50.2) 254 (52.7)
Main indication, n (%)
Known CAD 12,936 (18) 6587 (12) 6349 (34) 5758 (34) 448 (39) 143 (30)
Suspected CAD 15,016 (21) 4427 (8) 10,589 (57) 9677 (57) 606 (53) 306 (63)
Suspected/known CMP 12,856 (18) 12,448 (23) 408 (2) 376 (2) 28 (2) 4 (1)
Suspected/known
myocarditis
16,040 (22) 15,767 (29) 273 (1) 242 (1) 26 (2) 5 (1)
Others 15,991 (22) 15,056 (28) 935 (5) 868 (5) 43 (4) 24 (5)
CAD coronary artery disease, CMP cardiomyopathy, GBCA gadolinium-based contrast agent, SD standard deviation
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pharmacological stressor, GBCA, and main indication.
Age and gender were included in the model despite
statistical non-significance at the chosen alpha level to
adjust for potential confounding as described in the lit-
erature [3, 15]. Submitting institutions were considered
as random effects in the GLMM to account for differ-
ences in the underlying patient population or AAE as-
certainment methods. Results are presented in Table 3
and in the following paragraphs.
Pharmacological stress imaging
Patients undergoing stress test imaging were more likely
to develop acute adverse events of any severity com-
pared to non-stress imaging: patients receiving adeno-
sine, regadenoson, or dobutamine were more likely to
exhibit acute adverse events (OR = 2.31, 3.92, and 4.13,
respectively; p < 0.001, p < 0.001, and p = 0.002, re-
spectively). As shown in Table 2, adverse event severity
varied across pharmacological stressors: while severe
adverse events only occurred in adenosine stress
imaging (n = 7/16,921, 0.041%), the majority of adverse
events in regadenoson stress imaging were of moderate
severity (n = 29/1151 [absolute, 2.52%; relative, 85.3%])
and mainly attributable to dyspnea (n = 24).
GBCA
In comparison to gadobutrol , pat ients receiving
gadobenate, gadopentetate, and gadoteridol were more
likely to develop acute adverse events, and those receiv-
ing gadodiamide and gadoteric acid were less likely to
develop acute adverse events. Findings reached statistical-
ly significance at the chosen alpha level for gadoteridol
(OR = 3.58, 95% CI = 1.83–6.99, p < 0.001), independent
from the following covariates: pharmacological stressor,
main indications, age, and gender.
There was a statistically significant multiplicative in-
teraction between pharmacological stressors and GBCAs
(p = 0.0252 for the 15-degree-of-freedom interaction test
between GBCA and pharmacological stressor). For ex-
ample, there was a ninefold increase in gadobutrol-




















Acute adverse events, n (%)
No 72,579 (99.64) 54,165 (99.78) 18,414 (99.25) 16,822 (99.41) 1117 (97.05) 475 (98.55)
Yes 260 (0.36) 120 (0.22) 140 (0.75) 99 (0.59) 34 (2.95) 7 (1.45)
Adverse events, n (%)
Physiologic adverse
events (n = 184,
71%)
Mild Back pain 2 (0.003) 1 (0.002) 1 (0.005) – 1 (0.087) –
Mild Emesis 17 (0.023) 11 (0.020) 6 (0.032) 5 (0.030) – 1 (0.207)
Mild Heating 6 (0.008) 2 (0.004) 4 (0.022) 2 (0.012) 2 (0.174) –
Mild Others 4 (0.005) – 4 (0.022) 4 (0.024) – –
Mild Anxiety 17 (0.023) 4 (0.007) 13 (0.070) 8 (0.047) 2 (0.174) 3 (0.622)
Moderate Angina
pectoris
13 (0.018) 4 (0.007) 9 (0.049) 7 (0.041) 2 (0.174) –
Moderate Dyspnea 88 (0.121) 26 (0.048) 62 (0.334) 35 (0.207) 24 (2.085) 3 (0.622)
Moderate Symptomatic
bradycardia
12 (0.016) 4 (0.007) 8 (0.043) 6 (0.035) 2 (0.174) –
Moderate Symptomatic
hypertension
2 (0.003) 2 (0.004) – – – –
Moderate Symptomatic
hypotension
6 (0.008) 4 (0.007) 2 (0.011) 2 (0.012) – –
Severe Arrhythmia 13 (0.018) 11 (0.020) 2 (0.011) 2 (0.012) – –
Severe Renal failure 1 (0.001) – 1 (0.005) 1 (0.006) – –
Severe Resuscitation 3 (0.004) 1 (0.002) 2 (0.011) 2 (0.012) – –
Allergic-like adverse
events (n = 76, 29%)
Mild Hypersensitive
reaction
61 (0.084) 41 (0.076) 20 (0.108) 19 (0.112) 1 (0.087) –
Moderate Respiratory
adverse event
8 (0.011) 4 (0.007) 4 (0.022) 4 (0.024) – –
Severe Severe allergic
reaction
7 (0.010) 5 (0.009) 2 (0.011) 2 (0.012) – –
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associated adverse event rates comparing adenosine to
regadenoson stress imaging (0.55% versus 4.56%),
while gadoteric acid–associated adverse event rates were
balanced (0.3% versus 0.47%).
Molecular structure, ionic properties, and thermody-
namic chelate stability of GBCA did not influence acute
adverse events at the chosen alpha level (cyclic versus
linear molecular structure: univariate OR = 0.76, 95%
CI = 0.51–1.15, p = 0.197; ionic versus non-ionic
GBCA: univariate OR = 1.16, 95% CI = 0.8–1.69, p =
0.43; log Ktherm: univariate OR = 1.04, 95% CI = 0.93–
1.15, p = 0.492, respectively, using GLMM with submit-
ting institution as random effect). Acute adverse event
rates across different GBCAs with corresponding molec-
ular structure, ionic properties, and thermodynamic stabil-
ity, as well as pharmacological stressors, are presented in
Table 4. Specific acute adverse events for each GBCA
subtype are further detailed in the supplemental material.
Main indications
Compared to patients with known CAD, those with imag-
ing indications (suspected/known cardiomyopathy, myo-
carditis, and other indications) were less likely to develop
acute adverse events (OR = 0.59 [p = 0.044], OR = 0.52
[p = 0.016], and OR = 0.59 [p = 0.036], respectively).
Sensitivity analyses
When analyzing the outcome allergic-like and physiologicAAEs
separately, results for any acute adverse event were confirmed.
For example, parameter estimates for gadoteridol were of com-
parable magnitude and direction (OR = 1.85 [p = 0.221] and
OR = 4.98 [p < 0.001], respectively; see the supplemental
material).
Further, GBCAvolume and concentration were assessed in
a subset of patients with available data (n = 18,849) as detailed
in the supplemental material. In a multivariable model includ-
ing GBCA volume, concentration, and GBCA subtype, there
was marginal statistical evidence that higher GBCA volume
was associated with a higher AAE likelihood (OR = 1.018 per
1 ml increment, p = 0.051). Although this effect did not persist
after inclusion of the variable stress test imaging, it might be
indicative that increased GBCA volume is associated with
higher AAE likelihood. This association is further supported
by a higher mean GBCA volume in the subgroup of severe
physiologic AAEs (20.7 ml) compared to moderate AAEs
(16.6 ml), as shown in the supplemental material.
Table 3 Final multivariable
logistic regression model for the
outcome acute adverse event
using a GLMM with submitting
institution as random effect
Covariate Molarity (mmol/ml) Odds ratio 95% CI p value
Lower Upper
Age 0.992 0.985 1 0.064
Gender
Male Reference
Female 1.089 0.839 1.415 0.52
MR stress test
No stress test Reference
Adenosine stress test 2.311 1.559 3.426 < 0.001
Regadenoson stress test 3.922 2.258 6.81 < 0.001
Dobutamine stress test 4.134 1.7 10.052 0.002
GBCA
Gadobutrol (i.e., Gadovist®) 1.0 Reference
Gadobenate (i.e., MultiHance®) 0.5 1.546 0.88 2.715 0.13
Gadodiamide (i.e., Omniscan®) 0.5 0.734 0.192 2.811 0.651
Gadopentetate (i.e., Magnevist®) 0.5 1.711 0.947 3.092 0.075
Gadoteric acid (i.e., Dotarem®) 0.5 0.89 0.533 1.486 0.656
Gadoteridol (i.e., ProHance®) 0.5 3.58 1.832 6.995 < 0.001
Main indication
Known CAD Reference
Suspected CAD 0.968 0.695 1.348 0.847
Suspected/known CMP 0.589 0.352 0.985 0.044
Suspected/known myocarditis 0.523 0.308 0.888 0.016
Other main indications 0.593 0.365 0.966 0.036
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Discussion
The overall rate of acute adverse events (AAEs) in our multi-
national, multicenter cohort was 0.36%. This finding is in line
with the literature onGBCA application in general and cardiac
imaging in specific, ranging from 0.04 to 2.2% [1–7, 13,
18–21].
However, AAEs were more frequent compared to the
EuroCMR Registry in 2011 and 2015, reporting AAE rates
of 0.12–0.17%, while using the same ACR classification.
In particular, the number of moderate and severe AAEs
was higher in the ESCR MRCT Registry: 40%, 50.8%, and
9.2% of the reported acute adverse events were mild, moder-
ate, and severe, compared to 17.2% moderate and up to 6.3%
severe adverse events in the EuroCMRRegistry [6]. However,
the latter study did not explicitly include cardiac stress test
imaging. Differences in AAE rates could be further attributed
to multiple factors, including diverging sample sizes and un-
derlying population, selection bias related to discrepancies in
documentation compliance and adverse event awareness, as
well as differences in stress examinations and contrast agent
usage. In this context, it has to be highlighted that the most
frequent severe AAEs in our study were arrhythmias, which
might be attributable to underlying cardiac disease in this spe-
cific patient population as well.
Our study population of 72,839 patients is the largest cohort
evaluating AAEs in CMR imaging when compared to 37,788
[5] or 17,767 [13] patients in the EuroCMR Registry. Results
on a lower AAE rate in the EuroCMRRegistrymight be related
to a smaller cohort with less contribution—mainly academic
centers and countries (57 versus 263 centers and 15 versus 32
countries). Further, our study evaluated a significantly larger
proportion of male subjects (65% versus 62.2% male) [6].
In our study, the majority of patients demonstrated patho-
logical CMR scans. While comparable data is unavailable
from the EuroCMR Registry, one may speculate that the num-
ber of pathologic CMRs was lower than that in our cohort.
To the best of our knowledge, our study is the first to explicitly
evaluate the interaction and occurrence of AAEs in combined
stress CMR examinations with usage of GBCA. Only one
EuroCMR Registry study provided information on stress CMR
imaging, with severe AAEs (0.1%) reported exclusively in the
group of patients receiving stress CMR imaging [22]. Still,
EuroCMR Registry studies did not provide information on the
exact pharmacological stressor used. In the ESCR MRCT
Registry, regadenoson and dobutamine account for almost 10%
of stress imaging studies, which are associated with more AAEs,
i.e., due to a prolonged half-life and different modes of action as
compared to adenosine [23].
There were considerable differences in the GBCA distribu-
tion of our study (Fig. 1) compared to the most recent
EuroCMR Registry AAE study [6] with administration of
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(16.2%), and gadoteric acid (11.2%). However, the distribu-
tion of GBCA among vendors is substantially influenced by
submitting centers and does not necessarily reflect the actual
market shares in Europe.
Finally, discrepancies in documentation compliance and
adverse event awareness might contribute to the higher num-
ber of AAEs observed in the radiological ESCR MRCT
Registry as compared to the cardiology-initiated EuroCMR
Registry: cardiologists might underrate or fail to report mod-
erate AAEs such as dyspnea in the setting of stress CMR
imaging.
Adverse events risk factors
After multivariable statistical adjustment, pharmacological
stressors and GBCA subtypes emerged as independent, sig-
nificant predictors of acute adverse events. Patients subjected
to stress imaging were more likely to develop acute adverse
events than those without stress imaging. Across different
pharmacological stressors, regadenoson and dobutamine
showed an increased likelihood when compared to adenosine.
In line with the recent literature, adverse event rates were
higher among regadenoson and limited to mild and moderate
events, mainly dyspnea [24, 25]. This difference could be
attributed to the pharmacokinetic properties of regadenoson
with a comparably long, tri-phasic half-life time [23].
However, increased respiratory adverse events could originate
from selective regadenoson administration in patients with
pulmonary diseases as well [26]. Since pulmonary diseases
were not evaluated in the registry, residual confounding might
have distorted our results.
Our findings on higher adverse event rates disagree with
results from the EuroCMR Registry, showing lower adverse
event rates in stress imaging [5, 13]. However, the authors did
not statistically adjust for potential confounders such as age,
gender, and imaging indications.
Although not the main aim of our study, gadoteridol had a
higher likelihood than gadobutrol to be associated with acute
adverse events. Disparities in GBCA molecular structure and
chelate stability were suggested as potential explanations, sup-
ported by a recent meta-analysis showing increased AAE risk
for linear ionic GBCA [3, 14, 27, 28]. The missing statistical
influence of GBCA molecular properties in our study might
be attributable to the overall low number of AAEs and con-
secutively low statistical power in certain subgroups. Still,
comparisons between the GBCA subtypes were adequately
powered to detect very small effect sizes at 90–95% power
with an alpha level of 0.05, even considering the smallest
GBCA strata [29]. Concerns that imbalances in GBCA strata
sizes, ranging from approximately 2250 to 40,000 patients,
biased our results are not supported by the current statistical
literature [30].
Interestingly, GBCA-associated adverse events varied
across pharmacological stressors. For example, gadobutrol-
associated adverse event rates ranged from 0.52% for adeno-
sine to 4.56% for regadenoson, while event rates were bal-
anced for gadoteric acid (0.3% versus 0.47%). This might be
explained by a potentiation of contrast media–associated acute
events, depending on different pharmacological stressors, but
has not been described in the literature so far.
Although not statistically significant, subgroup analyses
suggest that higher GBCA volume might contribute to our
findings. For example, higher GBCA volumes were evident
in the regadenoson subgroup with high AAE incidence.
Further, severe AAEs were mainly categorized as physiologic
and received larger GBCA volumes compared to other strata.
Especially considering our patient cohort with known or
suspected cardiac impairment, intravenous fluid administra-
tion might intuitively correlate with AAE incidence, as de-
scribed for patients with acute decompensated heart failure
[31]. We aim to prospectively collect additional data on the
total amount of intravenous fluid administration with updated
versions of the MRCT Registry to further elucidate these
pathomechanisms.
In contrast to earlier studies, we analyzed routinely used
GBCAs and statistically adjusted for confounders.
Differences in the underlying patient population or varying
AAE ascertainment methods across the submitting centers
were considered in statistical analyses. Reporting on AAEs
in the context of CMR imaging was standardized in the
ESCR MRCT Registry and completed by physicians.
Finally, our results proved robust upon sensitivity analyses.
Still, our study is not devoid of limitations. Information on
GBCA concentration and volume were non-mandatory and
missing in the majority of cases, which might have biased results
on GBCA-specific AAE profiles. There was no information on
long-term follow-up, limiting the validity for late-onset adverse
events such as nephrogenic systemic fibrosis [32]. Despite a large
overall sample size, single stressor and GBCA subgroups might
be undersampled to promote generalizable conclusions. The
MRCT Registry was not specifically designed to evaluate
GBCA safety, and selection biases must be considered regarding
the non-random fashion in which stressor and contrast agents
were administered. For example, cardiac imaging for cardiomy-
opathywas conductedmainlywithout pharmacological stressors,
whereas stress imaging was performed in the majority of patients
with suspected or known CAD. Furthermore, patients receiving
regadenoson might have been selected due to underlying pulmo-
nary diseases, thus explaining a higher rate of respiratory acute
adverse events in the regadenoson subgroup. The proposed in-
teractions between stressor and GBCA need therefore to be val-
idated in randomized studies, controlling for underlying clinical
conditions. Moreover, results on GBCA-specific AAE rates
might be biased by selective data collection and reporting due
to the registry design and the retrospective analysis of our study.
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Finally, no information was obtained regarding the pa-
tients’ renal function and previous history of adverse reactions
to contrast media, which may have biased our results.
Conclusions
Our results suggest that gadolinium-based contrast agents
are generally safe for application in cardiac MR imaging.
Observed acute adverse event rates are within the range
reported for general radiology and differ across GBCA,
stress test imaging, and pharmacological stressor, as well
as main indications. Higher volume intravenous fluid ad-
ministration in patients with cardiac impairment might at
least partially contribute to our findings. Further, pharma-
cological stressors might potentiate GBCA-associated ad-
verse events. To the best of our knowledge, we provide
the largest and most comprehensive study for acute ad-
verse events in GBCA-enhanced cardiac MR imaging,
evaluating a variety of routinely used GBCA in a multi-
national, multicenter setting.
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